PATENT

Attorney's Docket No.: U 012951-1

IN THE UNITED STATES PATENT AND TRADEMARKING FILE

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231





NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of Inventors:

- 1. CHUN-YING HUANG
- 2. JIA-KANG WHANG-PENG
- 3. LI-TZONG CHEN
- 4. TSANG-WU LIU
- 5. JANG-YANG CHANG
- 6. MING-CHU HSU

WARNING: The Declaration must name all of the actual inventor(s).

For (title):

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA

1. Type of Application

This new application is for a(n) (check one applicable item below):

- ☑ Original (nonprovisional)
- ☐ Design
- □ Plant

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date JANUARY 24, 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL728210706US addressed to the: Assistant Commissioner of Patents, Washington, D.C. 20231

IBIS CARRILLO

(type or print name of person mailing paper)

(Signature of person mailing paper)

NOTE: Each paper or fee referred to as enclosed herein has the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 CFR 1.10(b).

WARNING:

Certificate of mailing (first class) or facsimile transmission procedures of 37 CFR 1.8 cannot be used to obtain a date of mailing or transmission for this correspondence.

(Application Transmittal [4-1]—page 1 of 7)



WARNING: Do not use this transmittal for a completion in the U.S. of an International Application under 35 U.S.C.

371(c)(4) unless the International Application is being filed as a divisional, continuation or continuation-in-

part application.

WARNING: Do not use this transmittal for the filing of a provisional application.

2. Benefit of Prior U.S. Application(s) (35 U.S.C. 119(e), 120, or 121)

NOTE: If the new application being transmitted is a divisional, continuation or a continuation-in-part of a parent case, or where the parent case is an International Application which designated the U.S., or benefit of a prior provisional application is claimed, then check the following item and complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

WARNING: If an application claims the benefit of the filing date of an earlier filed application under 35 U.S.C. 120, 121 or 365(c), the 20-year term of that application will be based upon the filing date of the earliest U.S. application that the application makes reference to under 35 U.S.C. 120, 121 or 365(c). (35 U.S.C. 154(a)(2) does not take into account, for the determination of the patent term, any application on which priority is claimed under 35 U.S.C. 119, 365(a) or 365(b).) For a c-i-p application, applicant should review whether any claim in the patent that will issue is supported by an earlier application and, if not, the applicant should consider canceling the reference to the earlier filed application. The term of a patent is not based on a claim-by-claim approach. See Notice of April 14, 1995, 60 Fed. Reg. 20,195, at 20,205.

WARNING: When the last day of pendency of a provisional application falls on a Saturday, Sunday, or Federal holiday within the District of Columbia, any nonprovisional application claiming benefit of the provisional must be filed prior to the Saturday, Sunday or Federal holiday within the District of Columbia. See 37 C.F.R. § 1.78(a)(3).

The new application being transmitted claims the benefit of prior U.S. application(s) and enclosed are ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.

NOTE: If one of the following 3 items apply, then complete and attach ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF A PRIOR U.S. APPLICATION CLAIMED and a NOTIFICATION IN PARENT APPLICATION OF THE FILING OF THIS CONTINUATION APPLICATION.

Divisional.
Continuation.
Continuation-in-Part (C-I-P).

3. Papers Enclosed That Are Required For Filing Date Under 37 CFR 1.53 (Regular) or 37 CFR 1.153 (Design) Application

	JO (L	Pesigni Application						
	Pag	es of specification						
1	Pag	es of claims						
1	Pages of Abstract							
7	She	ets of drawing						
	$\overline{\mathbf{A}}$	formal						
		informal						

WARNING: DO NOT submit original drawings. A high quality copy of the drawings should be supplied when filing a patent application. The drawings that are submitted to the Office must be on strong, white, smooth, and non-shiny paper and meet the standards according to § 1.84. If corrections to the drawings are necessary, they should be made to the original drawing and a high-quality copy of the corrected original drawing then submitted to the Office. Only one copy is required or desired. Comments on proposed new 37 CFR 1.84. Notice of March 9, 1988 (1990 O.G. 57-62).

NOTE: "Identifying indicia, if provided, should include the application number or the title of the invention, inventor's name, docket number (if any), and the name and telephone number of a person to call if the Office is unable to match




the drawings to the proper application. This information should be placed on the back of each sheet of drawing a minimum distance of 1.5 cm. (% inch) down from the top of the page." 37 C.F.R. 1.84(c).

(complete the following, if applicable)

		The AC	e enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO CEPT PHOTOGRAPH(S) AS DRAWING(S)". 37 C.F.R. 1.84(b).					
4.	Add	dition	al papers enclosed					
		Prel	liminary Amendment					
	\square	Info	ermation Disclosure Statement (37 CFR 1.98)					
	\square		m PTO-1449					
	\square	Cita	itions					
		Dec	laration of Biological Deposit					
		pert	mission of "Sequence Listing," computer readable copy and/or amendment caining thereto for biotechnology invention containing nucleotide and/or amino aciduence.					
		Aut	horization of Attorney(s) to Accept and Follow Instructions from Representative					
			cial Comments					
		Oth	er					
5.	Dec	larati	on or oath					
	\square	Encl	osed					
		exec	cuted by (check all applicable boxes)					
		$ \overline{\mathbf{A}} $	inventors.					
			legal representative of inventors. 37 CFR 1.42 or 1.43					
			joint inventor or person showing a proprietary interest on behalf of inventor who refused to sign or cannot be reached.					
			☐ This is the petition required by 37 CFR 1.47 and the statement required by 37 CFR 1.47 is also attached. See item 13 below for fee.					
		Not	Enclosed.					
WARNING:		availa Intern may i	the the filing is a completion in the U.S. of an International Application but where a declaration is not able or where the completion of the U.S. application contains subject matter in addition to the national Application the application may be treated as a continuation or continuation-in-part, as the case be, utilizing ADDED PAGE FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. ICATION CLAIMED.					
			Application is made by a person authorized under 37 CFR 1.41(c) on behalf of <i>all the above named inventors</i> . (The declaration or oath, along with the surcharge required by 37 CFR 1.16(e) can be filed subsequently).					
NOTE:	It is i	mporta	nt that all the correct inventor(s) are named for filing under 37 CFR 1.41(c) and 1.53(b).					
			□ Showing that the filing is authorized. (Not required unless called into question. 37 CFR 1.41(d).)					
6.	Inve	ntors	hip Statement					
WARN	IING:	If the of the	named inventors are each not the inventors of all the claims an explanation, including the ownership evarious claims at the time the last claimed invention was made, should be submitted.					
	The	inventorship for all the claims in this application are:						
		The	same					

(Application Transmittal [4-1]—page 3 of 7)




	Ц		the same. An explanation the last claimed invention	n, including the ownership o on was made,	t the various claims at the				
7.	Language								
NOTE:	An application including a signed oath or declaration may be filed in a language other than English. A verified English translation of the non-English language application and the processing fee of \$130.00 required by 37 CFR 1.17(k) is required to be filed with the application or within such time as may be set by the Office. 37 CFR 1.52(d).								
NOTE:	TE: A non-English oath or declaration in the form provided or approved by the PTO need not be translated. 1.69(b).								
	$\overline{\Delta}$	Eng	lish						
		non	-English						
			the attached translation	is a verified translation. 37 (CFR 1.52(d).				
8.	Ass	ignm	ent						
	\square	An	assignment of the inventi	on to TTY BIOPHARM COMF	PANY LIMITED				
				DE COVER SHEET FOR ASPATENT APPLICATION" or □					
		abla	will follow.						
NOTE:		_	nnment is submitted with a new a ignment." Notice of May 4, 195	application, send two separate letters 30 (1114 O.G. 77-78).	s—one for the application and one				
WARN	NG:			UNDER 37 CFR 3.73(b)" must be Notice of April 30, 1993. 1150 0.6					
9.	Cert	tified	Сору						
	Cert	tified	copy of application						
			Country	Appin. No.	Filed				
		Т	aiwan (R.O.C.)	89101826	February 2, 2000				
		f	rom which priority is clair	med					
		V	is attached.						
			will follow.						
NOTE:	The foreign application forming the basis for the claim for priority must be referred to in the oath or declaration 37 CFR 1.55(a) and 1.63.								
NOTE:	This item is for any foreign priority for which the application being filed directly relates. If any parent U.S. application or International Application from which this application claims benefit under 35 U.S.C. 120 is itself entitled to priority from a prior foreign application then complete item 18 on the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED.								
10.	Fee Calculation (37 CFR 1.16)								
	Α.	\boxtimes	Regular Application						
				Claims as Filed					



Number Filed						Ni	umber I	Extra	1	Rate	Basic Fee 37 CFR 1.16(a) \$710.00
Total (37 0		c))	8	- 20	=	0	х	\$	18.00		
Indepo (37 C				1	- 3	=	0	х	\$	80.00	-
	Multiple dependent claim(s), if any + \$ 270.00 (37 CFR 1.16(d))										
		An	nendment c	ancelli	ng ext	ra clai	ms enc	lose	d.		
		An	nendment d	eleting	multi	ple-de	penden	cies	end	losed.	
			e for extra c								
NOTE:	mei	ne fees nt, prid	s for extra clair.	ns are n tion of t	ot paid the time	on filing	g they mu set for re	ust b	e pai	d or the claims	cancelled by amend- d Trademark Office
							Filing F	ee (Calc	ulation \$	710.00
В.			sign applica 320.00 — 3		1.16(Filing F	ee (`alcı	ulation \$	
C.			nt applicatio 190.00 — 3		1.16(g))	Filing F				
11.	Sm	all Fr	ntity Statem	ant/e)			i iiiig i		Jaiot	ulation y	
	 Small Entity Statement(s) ✓ Verified Statement(s) that this is a filing by a small entity under 37 CFR 1.9 and 1.27 is(are) attached or has been filed. 										
		Fili	ng Fee Calcı	ulation	(50%	of A,	B or C	abo	ove)	\$	355.00
NOTE:	NOTE: Any excess of the full fee paid will be refunded if a verified statement and a refund request are filed within 2 months of the date of timely payment of a full fee. 37 CFR 1.28(a).										
12.											ete, if applicable)
		Plea		an inte	ernatio	nal-ty	pe sear	ch r	epo	rt for this an	plication at the
13.	Fee Payment Being Made At This Time										
		Not	Enclosed								
			No filing fo	ee is to ? <i>1.16</i>	o be p (e) car	aid at o <i>be p</i> a	this tim	ne. s <i>equ</i>	(Thi	s and the su ly.)	rcharge required
	$\overline{\mathbf{v}}$	Enc	losed								
		☑	basic filing	fee						\$	355.00

14.

15.



WARNING: While 37 CFR 1.17(a), (b), (c) and (d) deal with extensions of time under §1.136(a), this authorization should be made only with the knowledge that: "Submission of the appropriate extension fee under 37 C.F.R. 1.136(a) is to no avail unless a request or petition for extension is filed." (Emphasis added). Notice of November 5,1985 (1060 O.G. 27)



☑ 37 CFR 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 CFR 1.311(b))

NOTE: Where an authorization to charge the issue fee to a deposit account has been filed before the mailing of a Notice of Allowance, the issue fee will be automatically charged to the deposit account at the time of mailing the notice of allowance. 37 CFR 1.311(b).

NOTE: 37 CFR 1.28(b) requires "Notification of any change in loss of entitlement to small entity status must be filed in the application ... prior to paying, or at the time of paying, ... issue fee". From the wording of 37 CFR 1.28(b):

(a) notification of change of status must be made even if the fee is paid as "other than a small entity" and (b) no notification is required if the change is to another small entity.

16. Instructions As To Overpayment

☑ credit Account No. 12-0425

□ refund



Reg. No. 25,858

Tel. No. (212) 708-19 36

William R. Evans Ladas & Parry 26 West 61 Street New York, NY 10023

_	Incorporation	ı by	reference	of	added	l pages
---	---------------	------	-----------	----	-------	---------

(Check the following item if the application in this transmittal claims the benefit of prior U.S. application(s) (including an international application entering the U.S. stage as a continuation, divisional or C-I-P application) and complete and attach the ADDED PAGES FOR NEW APPLICATION TRANSMITTAL WHERE BENEFIT OF PRIOR U.S. APPLICATION(S) CLAIMED)

Plus Added Pages for New Application Transmittal Where Benefit of Prior U.S. Application(s) Claimed

Number of pages added ____

☐ Plus Added Pages for Papers Referred to in Item 4 Above

Number of pages added ____

☐ Plus "Assignment Cover Letter Accompanying New Application"

Number of pages added

(If no further pages form a part of this Transmittal, then end this Transmittal with this page and check the following item:)

☑ This transmittal ends with this page.